Stock PASG PASSAGE BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Passage Bio, Inc.

Equities

PASG

US7027121000

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 14:33:06 29/04/2024 BST 		5-day change 1st Jan Change
1.305 USD -1.11% Intraday chart for Passage Bio, Inc. +14.50% +29.24%
03-04 Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-04 Passage Bio, Inc. Appoints Kathleen Borthwick as Chief Financial Officer CI

Business Summary

Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.

Number of employees: 58

Managers

Managers TitleAgeSince
William Chou CEO
 Chief Executive Officer 51 09/10/22
James M. Wilson FOU
 Founder - 30/06/17
Kathleen Borthwick DFI
 Director of Finance/CFO 48 31/10/21
Mark Forman CTO
 Chief Tech/Sci/R&D Officer 60 29/07/21
Andrea Campanile CTO
 Chief Tech/Sci/R&D Officer - -
Alex Fotopoulos CTO
 Chief Tech/Sci/R&D Officer 55 30/06/19
Stuart M. Henderson IRC
 Investor Relations Contact - 31/01/21
Edgar Cale LAW
 General Counsel 60 31/08/19

Members of the board

Members of the board TitleAgeSince
Maxine Gowen CHM
 Chairman 66 17/02/21
Michael Kamarck BRD
 Director/Board Member 73 01/07/22
Saqib Islam BRD
 Director/Board Member 54 28/03/19
Athena Countouriotis BRD
 Director/Board Member 52 31/01/20
Sandipkumar S. Kapadia BRD
 Director/Board Member 53 30/11/19
Derrell Porter BRD
 Director/Board Member 53 26/05/21
William Chou CEO
 Chief Executive Officer 51 09/10/22
Dolan Sondhi BRD
 Director/Board Member - 26/07/23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 61,611,796 61,311,149 ( 99.51 %) 0 99.51 %

Shareholders

NameEquities%Valuation
OrbiMed Advisors Private Equity
18.21 %
10,124,576 18.21 % 14 M $
Lynx1 Capital Management LP
8.716 %
4,845,871 8.716 % 7 M $
New Leaf Venture Partners LLC
4.493 %
2,497,922 4.493 % 3 M $
Tang Capital Management LLC
4.317 %
2,400,000 4.317 % 3 M $
Vanguard Global Advisers LLC
3.631 %
2,018,882 3.631 % 3 M $
Renaissance Technologies LLC
2.200 %
1,223,351 2.200 % 2 M $
BlackRock Advisors LLC
1.724 %
958,387 1.724 % 1 M $
Millennium Management LLC
1.418 %
788,175 1.418 % 1 M $
Acadian Asset Management LLC
1.088 %
604,678 1.088 % 816 315 $
Pale Fire Capital SE
1.045 %
581,257 1.045 % 784 697 $

Company contact information

Passage Bio, Inc.

One Commerce Square 2005 Market Street

19103, Philadelphia

+

http://www.passagebio.com
address Passage Bio, Inc.(PASG)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.32 USD
Average target price
7 USD
Spread / Average Target
+430.30%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
PASSAGE BIO, INC. Stock Passage Bio, Inc.
+29.24% 81.33M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.99% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.90% 95.28B
ARGENX SE Stock argenx SE
+2.04% 22.15B
BIONTECH SE Stock BioNTech SE
-16.24% 21.02B
GENMAB A/S Stock Genmab A/S
-8.75% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.33% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.60% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.80% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. PASG Stock
  4. Company Passage Bio, Inc.